FUNDAMENTALS · Fundamentals · TW Healthcare

Pell Bio-Med Technology (6949) Fundamentals 2026 — Revenue Analysis | SniperIQ

Pell Bio-Med Technology (6949) is a TW-listed Healthcare company in Biotechnology with a market capitalization of NT$66.2B, trading at NT

010.00 on the TAI. This SniperIQ fundamentals page covers Pell Bio-Med Technology's valuation, profitability (net margin -1702.4%), revenue (NT
1M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapNT$66.2B
Net Margin-1702.4%
Revenue (FY25)NT
1M

Full research coverage

Frequently Asked Questions

What is Pell Bio-Med Technology's market cap?

Pell Bio-Med Technology (6949) has a market capitalization of approximately NT$66.2B, trading at NT

010.00 on the TAI. Market cap moves with the live share price.

What is Pell Bio-Med Technology's P/E ratio?

Pell Bio-Med Technology's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 24.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Pell Bio-Med Technology?

Pell Bio-Med Technology runs a net profit margin of -1702.4%, a gross margin of -61.1%, and an operating margin of -1823.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Pell Bio-Med Technology generate?

Pell Bio-Med Technology reported revenue of NT

1M for fiscal year 2025, with net income of -NT$424M and earnings per share (EPS) of -7.23. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Pell Bio-Med Technology pay a dividend?

Pell Bio-Med Technology does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Pell Bio-Med Technology financially healthy?

Pell Bio-Med Technology carries a debt-to-equity ratio of 0.09x and a current ratio of 9.60x, with a market beta of 0.91. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Pell Bio-Med Technology a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Pell Bio-Med Technology (6949) the key facts are: market cap NT$66.2B, revenue NT

1M, 52-week range 155-1120. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Pell Bio-Med Technology's full fundamentals live

Get Pell Bio-Med Technology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.